Preclinical Testing of Drug-Induced Proarrhythmia: Value of Transgenic Models

Title: Preclinical Testing of Drug-Induced Proarrhythmia: Value of Transgenic Models

Volume: 5 Issue: 4

Author(s): L. Fabritz, G. Breithardt and P. Kirchhof

Affiliation:

Keywords: Drug-induced proarrhythmia, repolarisation, long QT syndrome, action potential prolongation, torsades de pointes, transgenic model, experimental model, ion channels

Abstract: Drug-induced proarrhythmia is a serious medical problem that causes relevant morbidity and mortality. It is also a relevant problem for the development of novel pharmacological compounds. Therefore, there is a need for sensitive, specific and high-throughput preclinical tests to detect a risk for drug-induced proarrhythmia early in the development of new drugs. The review focuses on the potential role of transgenic models with altered repolarisation but without overt structural heart disease for drug-induced proarrhythmia screening. Today, selected murine models with alterations in K+, Na+ channels and ankyrin are available. In the future, transgenic rabbit and Zebra fish models may also be used.

Cite this article as:

Fabritz L., Breithardt G. and Kirchhof P., Preclinical Testing of Drug-Induced Proarrhythmia: Value of Transgenic Models, Cardiovascular & Hematological Agents in Medicinal Chemistry 2007; 5 (4) . https://dx.doi.org/10.2174/187152507782109881